Phenylethyl-beta-D-glucopyranoside and rhodioloside

Phenylethyl-beta-D-glucopyranoside has been researched along with rhodioloside* in 1 studies

Other Studies

1 other study(ies) available for Phenylethyl-beta-D-glucopyranoside and rhodioloside

ArticleYear
Discovery of Salidroside-Derivated Glycoside Analogues as Novel Angiogenesis Agents to Treat Diabetic Hind Limb Ischemia.
    Journal of medicinal chemistry, 2022, 01-13, Volume: 65, Issue:1

    Therapeutic angiogenesis is a potential therapeutic strategy for hind limb ischemia (HLI); however, currently, there are no small-molecule drugs capable of inducing it at the clinical level. Activating the hypoxia-inducible factor-1 (HIF-1) pathway in skeletal muscle induces the secretion of angiogenic factors and thus is an attractive therapeutic angiogenesis strategy. Using salidroside, a natural glycosidic compound as a lead, we performed a structure-activity relationship (SAR) study for developing a more effective and druggable angiogenesis agent. We found a novel glycoside scaffold compound (

    Topics: Angiogenesis Inducing Agents; Animals; Diabetes Mellitus, Experimental; Glucosides; Glycosides; Hindlimb; Ischemia; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Phenols; Rats; Rats, Sprague-Dawley

2022